ArticleMolecular diversity2026
Exploring the renoprotective potential of Beta vulgaris in diabetic nephropathy: an integrated network pharmacology, molecular docking and dynamics simulation study.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetic Nephropathy (DN) is a leading cause of end-stage renal failure globally. Beta vulgaris (BV), also known as beetroot, is a functional food that has shown promise in managing various metabolic disorders, including cancer, diabetes, cardiovascular disease, and liver disease, due to its anti-hypertensive, antioxidant, and anti-inflammatory properties. However, its role in DN and the underlying molecular mechanisms are not yet fully elucidated. Our study aimed to investigate the therapeutic potential of BV in DN through an integrated approach involving network pharmacology, molecular docking, and molecular dynamics simulation. The study identified 11 bioactive compounds from BV and 329 intersecting DN-related gene targets using databases such as IMPPAT, SwissTargetPrediction, DisGeNET, CTD, and GeneCards, all of which are related to DN. The protein-protein interaction networks constructed and visualized using STRING and Cytoscape v3.9.1, revealed key gene targets, including MAPK3, MAPK1, AKT1, IL1B, and MAPK14. Furthermore, GO and KEGG enrichment analysis highlighted their involvement in pathways such as the AGE-RAGE, PI3K-AKT, and cAMP signaling pathways. In addition, the molecular docking demonstrated significant binding energies (≤ - 5 kcal/mol) for bioactives such as Caffeic acid and Ferulic acid with MAPK1, MAPK3, and AKT1. Further, the MD simulation confirmed stable interactions for all proteins, emphasizing the BV's multi-pathway therapeutic mechanisms in the management of DN. Altogether, this computational study highlighted BV as a candidate nephroprotective agent, providing a comprehensive insight into its molecular mechanisms in treating DN. The integrated molecular mechanistic study highlighted the ameliorative role of BV against DN, which further paves the way for future research in DN therapeutics.
Indexed as
Identifiers
42176188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.